Genetic Risk Factors for Cirrhosis in Hemochromatosis Genetic Risk Factors for Cirrhosis in Hemochromatosis
This study identified gene variants which modulate the cirrhosis risk in hereditary hemochromatosis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 5, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Primary Biliary Cirrhosis (PBC) Treatment
Title: Primary Biliary Cirrhosis (PBC) TreatmentCategory: Diseases and ConditionsCreated: 8/21/2001 12:00:00 AMLast Editorial Review: 3/29/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - March 29, 2021 Category: Nutrition Source Type: news

Patients With Decompensated Cirrhosis Often Lack Advance Care Plans Patients With Decompensated Cirrhosis Often Lack Advance Care Plans
Many patients with decompensated cirrhosis do not have advance care plans in place to cover their trajectory of illness through end-of-life care, according to a new study that concludes this may be one reason they receive overly aggressive treatment.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 17, 2021 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news

Fatty liver disease symptoms: Six signs your condition has become irreversible
FATTY liver disease is pernicious because warning signs may only emerge in the later stages. If fatty liver disease progresses to cirrhosis , it cannot be reversed. Here are six warning signs of cirrhosis. (Source: Daily Express - Health)
Source: Daily Express - Health - March 16, 2021 Category: Consumer Health News Source Type: news

Targeted Albumin Not Better for Hospitalized Cirrhosis Patients
MONDAY, March 8, 2021 -- For patients hospitalized with decompensated cirrhosis, albumin infusions to raise the serum albumin level to a target of 30 g per liter or higher do not improve outcomes compared with standard care, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2021 Category: Pharmaceuticals Source Type: news

New AASLD Guidelines Reconsider Bleeding Risk in Cirrhosis New AASLD Guidelines Reconsider Bleeding Risk in Cirrhosis
Dr David Johnson comments on the paradigm-shifting implications of these guidelines on coagulation and bleeding in patients with cirrhosis.Medscape Gastroenterology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 4, 2021 Category: Intensive Care Tags: Gastroenterology Commentary Source Type: news

Oncotarget: Effect of liver fibrosis on survival in patients with intrahepatic cholangiocarcinoma
(Impact Journals LLC) The @Oncotarget authors aimed to assess the effect of cirrhosis on outcomes in iCCA patients (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2021 Category: Cancer & Oncology Source Type: news

Thiazolidinediones and Risk of MACE in T2DM and Cirrhosis Thiazolidinediones and Risk of MACE in T2DM and Cirrhosis
This study investigated the long-term cardiovascular outcomes of thiazolidinedione use in patients with type 2 diabetes and cirrhosis.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 25, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Operational guidelines launched for integration of Non-Alcoholic Fatty Liver Disease with NPCDCS
"Over the last two decades global burden of NASH has more than doubled. Globally, NASH caused 40 lakh prevalent cases of compensated cirrhosis in 1990, which increased to 94 lakh cases in 2017. NAFLD is emerging as an important cause of liver disease in India," Vardhan was quoted as saying in a Health Ministry statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 22, 2021 Category: Pharmaceuticals Source Type: news

AGA Practice Update: Bariatric Surgery in Patients With Cirrhosis AGA Practice Update: Bariatric Surgery in Patients With Cirrhosis
According to one study cited in the update, approximately 30% of patients with cirrhosis have comorbid obesity, and this figure may increase even further as the epidemic of NAFLD progresses.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 8, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

As alcohol abuse rises amid pandemic, hospitals see a wave of deadly liver disease
UCLA, USC and hospitals nationwide are treating more patients for alcoholic hepatitis, cirrhosis and other conditions amid COVID-19 shutdowns. (Source: L.A. Times - Health)
Source: L.A. Times - Health - February 8, 2021 Category: Consumer Health News Authors: Eli Cahan Source Type: news

Rifaximin May Prevent Hepatic Encephalopathy After TIPS Placement for Cirrhosis Rifaximin May Prevent Hepatic Encephalopathy After TIPS Placement for Cirrhosis
The antibiotic rifaximin given before and after transjugular intrahepatic portosystemic shunt (TIPS) placement helped prevent hepatic encephalopathy (HE) in a placebo-controlled trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 6, 2021 Category: Surgery Tags: Gastroenterology News Source Type: news

New combination therapy offers chance of healing hepatitis B
(German Center for Infection Research) Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as liver cirrhosis and liver cancer. A cure is not yet possible with the available medication. Scientists at the German Center for Infection Research (DZIF) and the University Hospital Eppendorf (UKE) have now investigated a new combination therapy that has proven highly effective in their infection model. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 4, 2021 Category: Infectious Diseases Source Type: news

Rifaximin Prevents Overt Hepatic Encephalopathy After TIPS
MONDAY, Feb. 1, 2021 -- For patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement, rifaximin used before and after the procedure is associated with a reduced risk for overt hepatic encephalopathy (HE),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2021 Category: Pharmaceuticals Source Type: news

Fatty liver disease symptoms: Melena is a sign of the condition
FATTY liver disease could progress to cirrhosis - scarring of the liver - if fat cells continue to build up in the life-supporting organ. How do you know if you're affected by the condition? What are the symptoms? (Source: Daily Express - Health)
Source: Daily Express - Health - January 30, 2021 Category: Consumer Health News Source Type: news

Widespread Liver Disease Missed in Patients With Type 2 Diabetes Widespread Liver Disease Missed in Patients With Type 2 Diabetes
Strikingly high prevalence rates of fatty liver disease, advanced fibrosis, and cirrhosis among patients with type 2 diabetes has led to calls for heightened awareness and screening.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 25, 2021 Category: Gastroenterology Tags: Diabetes & Endocrinology News Source Type: news

CT identifies patients with high-risk nonalcoholic fatty liver disease (NAFLD)
(American Roentgen Ray Society) According to ARRS' American Journal of Roentgenology, Fibrosis-4 and multiple CT findings can identify patients with high-risk nonalcoholic fatty liver disease--advanced fibrosis or cirrhosis, that is--though the presence of nonalcoholic steatohepatitis remains elusive on CT. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 22, 2021 Category: Cancer & Oncology Source Type: news

Terlipressin Has Stood the Test of Time Terlipressin Has Stood the Test of Time
This paper details the pharmacokinetics, pharmacodynamics and recent studies on the safety and efficacy of the investigational drug terlipressin in patients with cirrhosis.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 21, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Terlipressin Has Stood the Test of Time Terlipressin Has Stood the Test of Time
This paper details the pharmacokinetics, pharmacodynamics and recent studies on the safety and efficacy of the investigational drug terlipressin in patients with cirrhosis.Liver International (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - January 21, 2021 Category: Intensive Care Tags: Gastroenterology Journal Article Source Type: news

SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question, Lancet Gastroenterology and Hepatology
Amongst other points, article highlights that patients with cirrhosis are likely to have attenuated immune responses with vaccination. Nonetheless, given the high COVID-19-related mortality in these patients, it remains important to prioritise vaccination in this subgroup. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 13, 2021 Category: Consumer Health News Source Type: news

In Cirrhosis, Women Have Worse Frailty Scores Than Men
MONDAY, Jan. 4, 2021 -- Among patients with cirrhosis, women have worse frailty scores than men, which accounts for part of the gender gap in mortality while awaiting liver transplantation, according to a study published online Dec. 30 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2021 Category: Pharmaceuticals Source Type: news

Association between new-onset liver cirrhosis and suicide risk in South Korea: a nationwide cohort study - Jang SY, Rou WS, Kim SH, Lee BS, Eun HS.
Background& Aims: Current evidence suggests that liver cirrhosis (LC) causes severe psychological stress and depression, which are risk factors for suicide. Although previous studies reported the association between LC and suicidal thoughts, little is kno... (Source: SafetyLit)
Source: SafetyLit - December 21, 2020 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Fibroscan Liver Stiffness After Anti-viral Treatment for HCV Fibroscan Liver Stiffness After Anti-viral Treatment for HCV
This study investigated whether liver stiffness pre- or post-anti-viral therapy is associated with the development of decompensated cirrhosis, hepatocellular carcinoma, or death.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 16, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Cirrhosis Cases Rising Among Women in North America
MONDAY, Nov. 23, 2020 -- Cirrhosis disease burden in women has increased substantially since 2000, according to a study presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, held virtually... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Aspirin and Statins in Chronic Hepatitis B: It's Complicated Aspirin and Statins in Chronic Hepatitis B: It's Complicated
Statins play a bigger part than aspirin in reducing risk for hepatocellular carcinoma in patients with hepatitis B, new research shows, and cirrhosis seems to cancel any beneficial effect of aspirin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Safety, Tolerability of Elbasvir/grazoprevir in Chronic HCV Safety, Tolerability of Elbasvir/grazoprevir in Chronic HCV
This study evaluated the safety and tolerability of the two-drug oral combination of elbasvir and grazoprevir in individuals with HCV genotype 1 or 4, with and without cirrhosis.Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 13, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Cirrhosis, Child-Pugh Score Predict ERCP Complications Cirrhosis, Child-Pugh Score Predict ERCP Complications
The risk for complications related to endoscopic retrograde cholangiopancreatography (ERCP) could be elevated in patients with cirrhosis, according to a retrospective study of almost 700 patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 4, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Nobel prize in medicine awarded to US-UK trio for work on hepatitis C
Harvey Alter, Michael Houghton, Charles Rice share 10m Swedish kronor prizeTwo Americans and a British scientist have been awarded the Nobel prize in medicine for their groundbreaking work on blood-borne hepatitis, a health problem that causes cirrhosis and liver cancer around the world.Harvey J Alter at the US National Institutes of Health in Maryland, Charles M Rice from Rockefeller University in New York, and Michael Houghton, a British virologist at the University of Alberta in Canada, were honoured for their joint discovery of the hepatitis C virus, a major cause of liver disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 5, 2020 Category: Science Authors: Ian Sample Science editor Tags: Nobel prizes Science UK news Medicine Science prizes People in science Nobel prize in literature Awards and prizes Source Type: news

3 Win Nobel Medicine Prize for Discovering Hepatitis C Virus
(STOCKHOLM) — Americans Harvey J. Alter and Charles M. Rice and British-born scientist Michael Houghton won the Nobel Prize for medicine on Monday for their discovery of the hepatitis C virus, a major source of liver disease that affects millions worldwide. Announcing the prize in Stockholm, the Nobel Committee noted that the trio’s work identified a major source of blood-borne hepatitis that couldn’t be explained by the previously discovered hepatitis A and B viruses. Their work, dating back to the 1970s and 1980s, has helped saved millions of lives, the committee said. “Thanks to their discovery, ...
Source: TIME: Science - October 5, 2020 Category: Science Authors: DAVID KEYTON and FRANK JORDANS / AP Tags: Uncategorized News News Desk wire Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Researchers discover gene that could decrease likelihood of developing alcoholic cirrhosis
(Indiana University School of Medicine) Researchers at Indiana University School of Medicine are learning more about how a person's genes play a role in the possibility they'll suffer from alcoholic cirrhosis with the discovery of a gene that could make the disease less likely. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2020 Category: International Medicine & Public Health Source Type: news

Tools Emerging to Predict Liver Failure in Cirrhosis Tools Emerging to Predict Liver Failure in Cirrhosis
Systemic inflammation and portal hypertension can help predict whether a patient hospitalized for acute decompensated cirrhosis will develop acute-on-chronic liver failure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

New gene associated with reduced risk for cirrhosis
NIH-funded study provides hope for better disease prediction. (Source: NIAAA News)
Source: NIAAA News - August 31, 2020 Category: Addiction Authors: Katherine Source Type: news

New gene associated with reduced risk for cirrhosis
NIH-funded study provides hope for better disease prediction. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 31, 2020 Category: American Health Source Type: news

Depression and anxiety are common among patients with cirrhosis - Hernaez R, Kramer JR, Khan A, Phillips J, McCallister K, Chaffin K, Hernandez AP, Fullington H, Ortiz C, Blackwell JM, Loewen A, Liu Y, Tiro JA, Lee SC, Singal AG.
BACKGROUND AIMS: Depression and anxiety can have negative effects on patients and are important to treat. There have been few studies of their prevalence among patients with cirrhosis. We aimed to characterize the prevalence and risk factors for depression... (Source: SafetyLit)
Source: SafetyLit - August 30, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Fecal Transplant Shows Promise in Reducing Alcohol Craving Fecal Transplant Shows Promise in Reducing Alcohol Craving
Fecal transplantation for end-stage cirrhosis improves microbiome diversity, reduces alcohol cravings, and improves quality of life, a new safety study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

When liver cirrhosis is deadly
(Goethe University Frankfurt) A study by an international team of researchers headed by Professor Jonel Trebicka from the Frankfurt University Hospital and funded by the foundation EF Clif, has discovered which patients are particularly at risk for acute-on-chronic liver failure. With their findings, the scientists have laid the foundation for the development of preventive therapy to prevent acute-on-chronic liver failure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 27, 2020 Category: International Medicine & Public Health Source Type: news

Repeat FIB-4 Blood Tests Help Predict Cirrhosis Repeat FIB-4 Blood Tests Help Predict Cirrhosis
The difference between one fibrosis-4 (FIB-4) score and the next can predict risk for severe liver disease, new research shows, and can provide useful information to primary care doctors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Strides Pharma gets USFDA nod for Ursodiol tablets, a liver disease treatment drug
Strides Pharma Science gets an approval from the USFDA to market Ursodiol tablets used for treating primary biliary cirrhosis, a progressive disease of the liver caused by a buildup of bile within the liver. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 20, 2020 Category: Pharmaceuticals Source Type: news

TGen review suggests postmenopausal women at risk for nonalcoholic fatty liver disease
(The Translational Genomics Research Institute) NAFLD is the most common cause of liver damage, and can lead to liver cirrhosis and death. It affects nearly 1 in 4 people across the globe. It often is associated with obesity, abnormally high amounts of lipids in the blood, and type 2 diabetes. In the US, the number of NAFLD cases is expected to grow to more than 100 million within the next decade, annually costing an estimated at $292 billion. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 14, 2020 Category: International Medicine & Public Health Source Type: news

Resoundant expands its clinical research services
Medical technology company Resoundant is expanding its clinical research services...Read more on AuntMinnie.comRelated Reading: MRI scoring system could predict liver transplant need New MRI contrast material promises earlier liver diagnosis 2D shear-wave elastography diagnoses cirrhosis New AI platform, CT scanner pace GE launches at RSNA 2018 Elastography helps diagnose pediatric liver fibrosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 12, 2020 Category: Radiology Source Type: news

Acute on Chronic Liver Failure From Novel SARS-CoV-2 Acute on Chronic Liver Failure From Novel SARS-CoV-2
The authors report on a case of acute on chronic liver failure caused by SARS-CoV-2 infection in a patient with decompensated alcoholic cirrhosis.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 31, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

HCC in Chronic HCV Patients Who Achieved SVR HCC in Chronic HCV Patients Who Achieved SVR
Does achieving SVR with DAAs reduce the incidence of hepatocellular carcinoma in chronic hepatitis C patients, genotype IV with liver cirrhosis and advanced hepatic fibrosis?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 17, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Women Suffer Less NAFLD but More Advanced Fibrosis Women Suffer Less NAFLD but More Advanced Fibrosis
Given the higher risk of advanced fibrosis among women compared to men with NAFLD, it is plausible that cirrhosis and its complications may occur with greater frequency among women than in men.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 16, 2020 Category: Gastroenterology Tags: Ob/Gyn & Women ' s Health News Source Type: news

Fat cell hormone boosts potential of stem cell therapy
(Osaka University) Mesenchymal stem cell (MSC) therapy has shown promising results in the treatment of conditions ranging from liver cirrhosis to retinal damage, but results can be variable. Using a mouse heart failure model, researchers led by Osaka University found that levels of a fat cell-derived hormone called adiponectin in the host significantly affect the efficacy of MSC therapy. Administration of a drug that increases adiponectin in combination with MSCs is therefore likely to significantly improve the clinical outcome. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 10, 2020 Category: Biology Source Type: news